FY2025 Earnings Forecast for PRE Issued By Cantor Fitzgerald

Prenetics Global Limited (NASDAQ:PRE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Prenetics Global in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($2.08) for the year. Cantor Fitzgerald has a "Overweight" rating and a $9.00 price objective on the stock. The consensus estimate for Prenetics Global's current full-year earnings is ($3.30) per share.

Prenetics Global (NASDAQ:PRE - Get Free Report) last announced its quarterly earnings data on Wednesday, November 27th. The company reported ($0.84) earnings per share (EPS) for the quarter. Prenetics Global had a negative return on equity of 16.45% and a negative net margin of 191.73%.

Prenetics Global Trading Down 3.3 %

PRE traded down $0.20 during midday trading on Wednesday, reaching $5.81. The company's stock had a trading volume of 1,472 shares, compared to its average volume of 10,513. The stock has a market cap of $51.67 million, a P/E ratio of -1.45 and a beta of -0.30. The company has a fifty day simple moving average of $5.28 and a 200 day simple moving average of $5.08. Prenetics Global has a twelve month low of $2.85 and a twelve month high of $7.84.

Prenetics Global Company Profile

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.